The EMA’s human medicines committee issued a positive opinion on Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of adult gMG patients who are anti-acetylcholine ...

The deal, which closed this week, marks the first acquisition for GMG, according to chief executive Ryan Harwood. Terms of the transaction were not disclosed. Coveteur will relaunch today ...